

## Limited Submission Funding Opportunities – updated 4/19/24

Please be aware that any grant that brings in less than 20% in indirect costs (IDC) will need to be supplemented up to the 20% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

For MGH investigators selected through a competitive process as the institutional nominee for any limited submission funding opportunities, in situations in which the grant will bring in less than 20% indirect cost (IDC), ECOR will cover the IDC gap up to a maximum of \$50,000 per year. In order to optimize the distribution of limited ECOR funds across the MGH research community, it is expected that PIs and departments will work together to cover the remaining IDC shortfall.

This policy is only effective for those limited submission opportunities in which MGH is invited to submit its own nominee(s). This policy does not apply for those limited submission opportunities in which the MGH investigator must apply through HMS.

For further questions, please contact ECOR at [ecor@mgh.harvard.edu](mailto:ecor@mgh.harvard.edu)

We ask that all MGH Investigators interested in applying for any limited submission award submit a Letter of Intent (see detailed instructions below) to the MGH Executive Committee on Research (ECOR) by the deadline indicated for each award to be considered to receive an institutional nomination.

### Process

Submit a one- to two-page Letter of Intent (LOI) to the MGH Executive Committee on Research (ECOR) via email to [ecor@mgh.harvard.edu](mailto:ecor@mgh.harvard.edu). In addition to your LOI, please include an NIH Biosketch.

The letter of intent should include:

1. Name of the Principal Investigator with appropriate contact information
2. A descriptive title of the potential application
3. Brief description of the project
4. Brief description of why you specifically should be selected to receive institutional nomination for this award

In the event that there is more than one MGH investigator interested in applying for a limited submission award, the LOIs will be used to assess candidates and a review and selection process will take place.

If there is a limited submission funding opportunity you do not see listed below or you have any additional questions, please let us know at [ecor@mgh.harvard.edu](mailto:ecor@mgh.harvard.edu).

### CURRENT OPPORTUNITIES

#### 1. Nathan Shock Centers Coordinating Center (U24 Clinical Trial Not Allowed)

This Notice of Funding Opportunity Announcement (NOFO) invites U24 applications to develop and maintain a Nathan Shock Centers Coordination Center (NSC3). The goal of the NSC3 is to provide logistical and organization support of the Nathan Shock Centers of Excellence in Basic Biology of Aging (NSC). Applicants should be familiar with NSC activities, but they do not need to be part of an NSC. Major activities of the proposed NSC3 will include improving visibility of the NSC nationally and internationally, improving collaboration and coordination among NSC, enhancing NSC training activities, facilitating the sharing of resources, and interacting with NIA and NSC to develop strategies and plans for further development. The successful application will include a plan to improve transparency and the interactions

## Limited Submission Funding Opportunities – updated 4/19/24

of NSC with the research community. It should also leverage existing bioinformatics resources. The NSC3 director will be a participant in the NIA's Research Centers Collaborative Network (RCCN).

**MGH LOI Deadline: 4/22/24**

NIH LOI Deadline: 5/15/24

NIH Application Deadline: 6/15/24

[Learn more](#)

### 2. 1907 Foundation Trailblazer Award – NEW!

The goal for the 1907 Trailblazer Award is to catalyze disruptive - but actionable - ideas which have the potential to unearth causes and cures for psychiatric and neurodegenerative diseases and uniquely require the 1907 Trailblazer Award to see the light of day. Embedded in this statement, there are three key phrases: i) psychiatric and neurodegenerative brain health, ii) disruptive, iii) causes & cures.

The 1907 Trailblazer Award was established to encourage high-impact, step-change approaches to research in the brain and mind sciences for psychiatric health. In addition to supporting a specific research project, the Award intends to increase the size of the talent pool of early career investigators researching causes and cures for psychiatric illness. They promote these aims by providing a US\$100,000 research grant on an unrestricted basis, a US\$20,000 prize to enhance the economic security of the scientist, and travel & expense coverage for attendance to in-person annual meetings. Each winner will be invited to present interim findings (year 1) and final findings (year 2), where they can form scientific relationships with other Fellows, our Science Innovation Committee and our Science Selection Committee.

In this vein, we hope to attract scientists who can think creatively across disciplines and who are motivated to swim against the tides of consensus. We want to see your outside-the-box ideas and methods, and we encourage applicants who have never received a major grant to apply. Projects must be grounded in the study of biological mechanisms underlying brain function, cognitive processes, and/or consciousness. We support projects for basic science in addition to near-term applications (e.g. disruptive technologies and potential clinical interventions).

**MGH LOI Deadline: 4/23/24**

Sponsor Application Deadline: 5/15/24

[Learn more](#)

### 3. NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 – Independent Clinical Trial Not Allowed)

The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to

## Limited Submission Funding Opportunities – updated 4/19/24

launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply.

*This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFOs ([PAR-23-287](#) or [PAR-23-288](#)).*

**MGH LOI Deadline: 4/30/24**

NIH Application Deadline: 6/14/24

[Learn more](#)

#### 4. NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 – Independent Clinical Trial Required)

The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply.

This notice of funding opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO ([PAR-23-286](#)).

**MGH LOI Deadline: 4/30/24**

NIH Application Deadline: 6/14/24

[Learn more](#)

#### 5. NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 – Independent Basic Experimental Studies with Humans Required)

The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their

## Limited Submission Funding Opportunities – updated 4/19/24

doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply.

This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO ([PAR-23-286](#)).

This Notice of Funding Opportunity is for basic science experimental studies involving humans, referred to in [NOT-OD-18-212](#) as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO.

The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

**MGH LOI Deadline: 4/30/24**

NIH Application Deadline: 6/14/24

[Learn more](#)